Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonsurf in advanced biliary tract cancers
NCT03278106Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trifluridine + tipiracil in biliary tract cancer (BTC), sponsored by Mayo Clinic. Primary endpoint: 16-Week Progression-free Survival Rate. Started Oct 2017; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03278106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278106.